

**Curriculum Vitae**

**Mgr. Radek Jorda, Ph.D.**

**Mailing Addresses and Contacts**

Department of Experimental Biology, Palacký University Olomouc, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic

phone: +420 58 5634854; fax: +420 58 5634870; e-mail:radek.jorda@upol.cz

personal email: radek.jorda@gmail.com

**Education and Positions**

2002 – 2005 Palacky University in Olomouc, Faculty of Science (Bc, M.Sc., Ph.D. degrees in Biochemistry)

2011 – 2012 Research assistant (Laboratory of Growth Regulators, Palacký University Olomouc, Czech Republic)

2012 – 2015 Junior research (Laboratory of Growth Regulators, Palacký University Olomouc)

Junior research (Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno)

2015 - 2022 Junior research (Laboratory of Growth Regulators, Palacký University Olomouc & Institute of Experimental Botany of the Czech Academy of Sciences)

since 2021 Researcher (Department of Experimental Biology, Palacký University Olomouc)

**Research Experiences**

2008-2009 (6 months) Structural Biochemistry Group, Centre for Translational and Chemical Biology, School of Biological Sciences, The University of Edinburgh, UK (prof. M. D. Walkinshaw)

2013-2014 (6 months) Phosphorylation and Cell Cycle Control Group, Institut de Génétique Moléculaire de Montpellier, CNRS, France (Dr. Daniel Fisher)

**Award**

2012 - the Sanofi Prize in Pharmacy (2nd Place)

**Research Interests**

Expression and purification of protein kinases, development of new modulators of protein kinases and nuclear receptors, scaffold hopping, biochemical and cellular characterization of novel modulators of kinases, nuclear receptors and proteasome.

**Participation in projects**

Supervisor

* GJ15-17282Y - Chemical genetic analysis of role of cyclin-dependent kinases in cancer cell lines (2015-2017)

Team member

* NV17-31834A – Targeting BCR signalosome in B-cell malignancies (2017-2020)
* GACR - 18-03847S – Pseudopeptides inhibitors of proteasome (2018-2020)
* GACR - 19-08410S - Substituted imidazopyrimidines: Structure-based design and development of specific inhibitors of cancer-related protein kinases (2019-2021)
* GACR - 20-25308S - Modulation of cyclin-dependent kinases for targeted treatment of tumors with molecularly defined deregulation G1/S phase of cell cycle (2020-2022)
* GACR - 21-07661S - Modulation of plant abiotic stress responses by regulation of cytokinin and purine interconversion enzymes (2021-2023)
* GACR - 21-06553S - Targeting oncogenic kinases with small molecules (2021-2024)

**Reviewer for Scientific Journals**

Expert Opinion On Drug Discovery, Expert Opinion On Drug Metabolism, Future Medicinal Chemistry, Journal of Medicinal Chemistry, Heliyon, ChemMedChem, Molecular Cancer Therapeutics, Therapeutic Advances in Medical Oncology, Bioorganic Chemistry, Molecules, South African Journal of Botany, Bioorganic & Medicinal Chemistry, Organic & Biomolecular Chemistry, Letters in Drug Design and Discovery, Steroids, European Journal of Medicinal Chemistry, Life Sciences, Frontiers in Molecular Biosciences

**WoS scientometric data** (publications and citation count, *h*‑index)

Results found: 73 (Author position – 27% first, 17% corresponding)

Sum of the Times Cited: 924

Sum of Times Cited without self-citations: 819

*h*-index: 19

**The most cited articles**

1. **Jorda R**, Havlíček L, McNae IW, Walkinshaw MD, Voller J, Šturc A, Navrátilová J, Kuzma M, Mistrík M, Bártek J, Strnad M, Kryštof V. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity. J Med Chem. 2011 Apr 28;54(8):2980-93. **(73 times cited)**
2. **Jorda R**, Paruch K, Kryštof V. Cyclin-dependent kinase inhibitors inspired by roscovitine: Purine bioisosteres. Curr Pharm Des. 2012;18(20):2974-80. **(55 times cited)**
3. **Jorda R**, Hendrychová D, Voller J, Řezníčková E, Gucký T, Kryštof V. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? J Med Chem. 2018 Oct 25;61(20):9105-9120. **(51 times cited)**
4. Gucký T, **Jorda R**, Zatloukal M, Bazgier V, Berka K, Řezníčková E, Béres T, Havlíček L, Kryštof V, Strnad M. A novel series of highly potent 2,6,9-trisubstituted purines as cyclin-dependent kinase inhibitors. J Med Chem. 2013 Aug 8;56(15):6234-47. **(43 times cited)**
5. Abo-Ashour MF, Eldehna WM, Nocentini A, Bonardi A, Bua S, Ibrahim HS, Elaasser MM, Kryštof V, **Jorda R**, Gratteri P, Abou-Seri SM, Supuran CT. 3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights. Eur J Med Chem. 2019 Dec 15;184:111768. **(41 times cited)**

**Teaching:**

KEB/EXBCV - Practices in Experimental Biology

KEB/IMMM - Interaction of Macromolecules with Ligands

KEB/EXBPR - Experimental Biology

LRR/IZVB - Protein databases and working with Pymol (1 lecture)

12 graduated students, 1 studying